Aduro BioTech Secures $19,250,000 Series B Funding Round

Feed Type
Link
http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=3763e8dd-0a7b-445d-b5ae-bf25bf93d29b&Preview=1
Date
4/20/2011
Company Name
Aduro BioTech
Mailing Address
626 Bancroft Way Berkeley, CA 94710
Company Description
Aduro BioTech is a clinical-stage immunotherapy company with a platform technology for therapeutic and prophylactic vaccines for cancer and infectious diseases. The platform of attenuated and targeted vaccines based on Listeria monocytogenes has been in development for nine years.
Website
http://www.adurobiotech.com
Transaction Type
Venture Equity
Transaction Amount
$19,250,000
Transaction Round
Series B
Proceeds Purposes
This new round of funding enables us to advance our lead cancer vaccine, CRS-207, into a Phase 2 clinical trial in pancreatic cancer. In addition, these funds will support initial clinical development of CRS-207 for other indications and preclinical development of therapeutic vaccines for prostate cancer and melanoma as well as prophylactic vaccines for malaria and tularemia.
M&A Terms
Venture Investor
Morningside Group
Venture Investor
Undisclosed